AUG 17, 2026 · PHASE 3 TRIAL
A Study Evaluating Adherence, Tolerability, and Patient Reported Outcomes of Giredestrant in Participants With ER+/HER2- Early Breast Cancer Who Are Intolerant to Adjuvant Aromatase Inhibitor Therapy (novERA Breast Cancer)
ClinicalTrials.gov
This is a Phase 3 trial registration with no results posted; the study is actively recruiting and primary outcomes have not yet been assessed.
Reported
Planned enrollment300
PhasePhase 3
Primary outcome: Discontinuation…12 months